Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov;56(11):1564-71.
doi: 10.1136/gut.2007.119750. Epub 2007 Mar 5.

Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer

Shuji Ogino  1 , Takako Kawasaki, Gregory J Kirkner, Yuko Suemoto, Jeffrey A Meyerhardt, Charles S Fuchs
Affiliations

Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer

Shuji Ogino et al. Gut. 2007 Nov.

Abstract

Background: The CpG island methylator phenotype (CIMP or CIMP-high) with widespread promoter methylation is a distinct epigenetic phenotype in colorectal cancer. In contrast, a phenotype with less widespread promoter methylation (CIMP-low) has not been well characterised. O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and silencing have been associated with G>A mutations and microsatellite instability-low (MSI-low).

Aim: To examine molecular correlates with MGMT methylation/silencing in colorectal cancer.

Methods: Utilising MethyLight technology, we quantified DNA methylation in MGMT and eight other markers (a CIMP-diagnostic panel; CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) in 920 population-based colorectal cancers.

Results: Tumours with both MGMT methylation and loss were correlated positively with MSI-low (p = 0.02), CIMP-high (>or=6/8 methylated CIMP markers, p = 0.005), CIMP-low (1/8-5/8 methylated CIMP markers, p = 0.002, compared to CIMP-0 with 0/8 methylated markers), KRAS G>A mutation (p = 0.02), and inversely with 18q loss of heterozygosity (p = 0.0002). Tumours were classified into nine MSI/CIMP subtypes. Among the CIMP-low group, tumours with both MGMT methylation and loss were far more frequent in MSI-low tumours (67%, 12/18) than MSI-high tumours (5.6%, 1/18; p = 0.0003) and microsatellite stable (MSS) tumours (33%, 52/160; p = 0.008). However, no such relationship was observed among the CIMP-high or CIMP-0 groups.

Conclusion: The relationship between MGMT methylation/silencing and MSI-low is limited to only CIMP-low tumours, supporting the suggestion that CIMP-low in colorectal cancer may be a different molecular phenotype from CIMP-high and CIMP-0. Our data support a molecular difference between MSI-low and MSS in colorectal cancer, and a possible link between CIMP-low, MSI-low, MGMT methylation/loss and KRAS mutation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Comment in

References

    1. Laird P W. Cancer epigenetics. Hum Mol Genet 200514(Spec No 1)R65–R76. - PubMed
    1. Issa J P. CpG island methylator phenotype in cancer. Nat Rev Cancer 20044988–993. - PubMed
    1. Wong J J, Hawkins N J, Ward R L. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 200756140–148. - PMC - PubMed
    1. Toyota M, Ahuja N, Ohe‐Toyota M.et al CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999968681–8686. - PMC - PubMed
    1. van Rijnsoever M, Grieu F, Elsaleh H.et al Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 200251797–802. - PMC - PubMed

Publication types